SELLAS Life Sciences SLS
NASDAQ SLS
$12.14 +0.16 (+1.34%)
At close: Oct 21, 2026 · 4:00 PM EDT

SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016)

Updated

SELLAS Life Sciences' Convertible Debt came in at $7.37 million for Q4 2016.

Analysis

SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016) Analysis & Trends

  • The Q4 2016 figure represents the lowest quarterly Convertible Debt since Q1 2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 SELLAS Life Sciences 2.30 Bn 1.94 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 7.37 Mn
Mar 31, 2012 1.00 Mn
API Access

SELLAS Life Sciences Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=SLS&period=max&api_key=YOUR_API_KEY